Avastin and Lucentis Equal in Treating Age-Related Macular Degeneration, Study Says

After two years of treatment, both Avastin and Lucentis are equivalent in improving vision loss resulting from age-related macular degeneration (AMD), according to research supported by the National Institutes of Health and published in the May 2012 issue of the journal Ophthalmology.

AMD is the primary cause of blindness among Americans over age 65. Although there is no cure for AMD, taking steps to prevent macular degeneration can help preserve your vision or slow the progress of AMD.

Taking Avastin or Lucentis on a monthly or as-needed basis prescribed by your ophthalmologist may also help improve vision damaged by the effects of AMD. Although Lucentis was approved by the Food and Drug Administration (FDA) specifically for the treatment of AMD, Avastin—a related drug that, like Lucentis, blocks the growth of abnormal blood vessels—is approved for the treatment of certain cancers including colon cancer.

Avastin has been administered to patients with AMD in clinical trials, and the recent study was the first to examine the results of both Lucentis and Avastin head-to-head after two years of repeated use. Researchers found that with regular administration, both Lucentis and Avastin led to a noticeable and lasting improvement in vision.

On average, patients taking the medications experienced vision improvement of about a half-line better on eye charts.

If you would like to learn more about macular degeneration treatment options, please contact Eyes.com to locate an ophthalmologist near you.